Clinical epidemiology of herpes zoster and postherpetic neuralgia in Barcelona (Spain). A single-center study

TL;DR

This study analyzed the clinical and epidemiological features of herpes zoster and postherpetic neuralgia in Barcelona, finding that older age and initial pain severity are key risk factors for PHN.

Contribution

The study provides new insights into the risk factors for postherpetic neuralgia, particularly highlighting the role of age and initial pain intensity.

Findings

HZ cases increased with age, with a female/male ratio of 1.38.

77.4% of patients had pain at rash onset, and 11.9% had pain at 90 days.

PHN risk was significantly higher in patients aged 70–79 and ≥80 years.

Abstract

Varicella-zoster virus is an alphaherpesvirus that causes two diseases in humans: chickenpox, the primary infection, and herpes zoster (HZ). Although HZ incidence has been well-documented, relatively little is known regarding the clinical-epidemiological characteristics of HZ prodromal pain, acute pain, and subacute pain. The aim of the study was to analyse the clinical-epidemiological characteristics of HZ and postherpetic neuralgia (PHN) in cases diagnosed between 2007 and 2020.

We conducted a clinical-epidemiological study of cases of HZ and PHN diagnosed between 2007 and 2020 in Hospital de Sagrado Corazón (Barcelona) in the first 14 days after rash onset, analyzing age, gender, dermatomes, and pain. Pain on rash diagnosis was classified as no pain, any pain, and clinically significant pain (scores 0, 1–10, and 3–10, respectively).

A total of 589 cases of HZ were included, mean age of patients was 59.6 years and the female/male ratio was 1.38 and cases increased with age (p < 0.01). Of the 589 cases, 77.4% had pain on day 0 of rash onset, 34.5% at 30 days, and 11.9% at 90 days. 70 cases progressed to PHN, which also increased with age. Factors associated with PHN were age groups 70–79 years (aOR 4.26; 95% CI 1.36–13.37) and ≥80 years (aOR 3.89; 95% CI 1.18–12.87) and intensity of pain score at rash onset ≥7 (aOR 19.74; 95% CI 4.63–84.10).

Patient age and pain presence and intensity on day 0 and at 30 days of HZ diagnosis are the main risk factors for PHN.

Tables

Table 1. Herpes zoster cases by pain category classified by age and gender.

Age, years	Overall	Men	Women	Female/male ratio
Overall
Median (range)	63 (6–99)	64 (6–89)	63 (7–99)
0–9	13 (2.2%)	8 (3.2%)	5 (1.5%)	0.62
10–19	37 (6.3%)	24 (9.7%)	13 (3.8%)	0.54
20–29	16 (2.7%)	6 (2.4%)	10 (2.9%)	1.67
30–39	30 (5.1%)	10 (4.0%)	20 (5.8%)	2.00
40–49	55 (9.3%)	17 (6.9%)	38 (11.1%)	2.23
50–59	96 (16.3%)	36 (14.6%)	60 (17.5%)	1.67
60–69	118 (20.0%)	46 (18.6%)	72 (21.1%)	1.56
70–79	120 (20.4%)	56 (22.7%)	64 (18.7%)	1.14
≥80	104 (17.7%)	44 (17.8%)	60 (17.5%)	1.36
All ages	589	247	342	1.38
Any pain
Mean ± SD	66 (7–99)	68 (7–89)	65 (11–99)
0–9	4 (0.9%)	4 (2.2%)	0 (0.0%)	0.00
10–19	9 (2.0%)	6 (3.3%)	3 (1.1%)	0.50
20–29	6 (1.3%)	3 (1.7%)	3 (1.1%)	1.00
30–39	21 (4.6%)	7 (3.9%)	14 (5.1%)	2.00
40–49	38 (8.3%)	10 (5.6%)	28 (10.1%)	2.80
50–59	81 (17.8%)	29 (16.1%)	52 (18.8%)	1.79
60–69	101 (22.1%)	38 (21.1%)	63 (22.8%)	1.66
70–79	108 (23.7%)	49 (27.2%)	59 (21.4%)	1.20
≥80	88 (19.3%)	34 (18.9%)	54 (19.6%)	1.59
All ages	456	180	276	1.53
Clinically significant pain
Mean ± SD	67 (7–99)	68 (7–89)	66 (11–99)
0–9	3 (0.7%)	3 (1.9%)	0 (0%)	0.00
10–19	8 (2.0%)	5 (3.2%)	3 (1.2%)	0.60
20–29	4 (1.0%)	2 (1.3%)	2 (0.8%)	1.00
30–39	19 (4.7%)	6 (3.8%)	13 (5.3%)	2.17
40–49	31 (7.7%)	8 (5.1%)	23 (9.3%)	2.87
50–59	73 (18.1%)	27 (17.2%)	46 (18.7%)	1.70
60–69	86 (21.3%)	31 (19.7%)	55 (22.4%)	1.77
70–79	99 (24.6%)	45 (28.7%)	54 (22.0%)	1.20
≥80	80 (19.9%)	30 (19.1%)	50 (20.3%)	1.67
All ages	403	157	246	1.57

Table 2. Herpes zoster cases by eruption site classified by age group.

Eruption site	Overall (N = 589)	< 50 years (N = 151)	≥50 years (N = 438)	p-value
Overall
Thoracic	206 (35.0%)	67 (44.3%)	139 (31.7%)	Ref.
Lumbar	117 (19.8%)	27 (17.9%)	90 (20.6%)	0.07
Cranial	106 (18.0%)	19 (12.6%)	87 (19.9%)	0.01
Cervical	70 (11.9%)	17 (11.3%)	53 (12.1%)	0.20
Sacral	86 (14.6%)	21 (13.9%)	65 (14.8%)	0.17
Disseminated	4 (0.7%)	0 (0%)	4 (0.9%)	0.99
Any pain (score 1–10)
Thoracic	153 (33.6%)	29 (37.2%)	124 (32.8%)	Ref.
Lumbar	91 (20.0%)	15 (19.2%)	76 (20.1%)	0.63
Cranial	92 (20.2%)	17 (21.8%)	75 (19.8%)	0.93
Cervical	52 (11.4%)	8 (10.3%)	44 (11.6%)	0.56
Sacral	65 (14.3%)	9 (11.5%)	56 (14.8%)	0.36
Disseminated	3 (0.7%)	0 (0%)	3 (0.8%)	0.99
Clinically significant pain (score 3–10)
Thoracic	139 (34.5%)	26 (40.0%)	113 (33.4%)	Ref.
Lumbar	81 (20.1%)	12 (18.5%)	69 (20.4%)	0.46
Cranial	74 (18.4%)	13 (20.0%)	61 (18.0%)	0.84
Cervical	49 (12.2%)	7 (10.8%)	42 (12.4%)	0.49
Sacral	58 (14.4%)	7 (10.8%)	51 (15.1%)	0.26
Disseminated	2 (0.5%)	0 (0%)	2 (0.6%)	0.99

Table 3. Herpes zoster cases by pain category at different disease stages classified by age group.

Disease stage	Overall (N = 589)	< 50 years (N = 151)	≥50 years (N = 438)	p-value
No pain (score 0)	133 (22.6%)	73 (48.3%)	60 (13.7%)
Pain day 0	456 (77.4%)	78 (51.7%)	378 (86.3%)
Any pain (score 1–10)
Day 0 of rash onset	456 (77.4%)	78 (51.7%)	378 (86.3%)	< 0.01
Day 30 of rash onset	203 (34.5%)	18 (11.9%)	185 (42.3%)	< 0.01
Day 90 of rash onset	70 (11.9%)	4 (2.6%)	66 (15.1%)	< 0.01
Clinically significant pain (score 3–10)
Day 0 of rash onset	403 (68.4%)	65 (43.0%)	338 (77.2%)	< 0.01
Day 30 of rash onset	186 (31.6%)	15 (9.9%)	171 (39.0%)	< 0.01
Day 90 of rash onset	67 (11.4%)	4 (2.6%)	63 (14.4%)	< 0.01

Table 4. Herpes zoster pain characteristics by age at different disease stages.

Characteristics	Overall N = 589	Day 0 N = 456	Day 30 N = 203	Day 90 N = 70	p-value*	p-value**
Any pain (score 1–10)
With pain	456 (77.4%)	203 (34.5%)	70 (11.9%)
<50 years	151	78 (51.6%)	18 (11.9%)	4 (2.6%)	0.01	0.44
50–59 years	96	81 (84.4%)	29 (30.2%)	8 (8.3%)	0.23	0.60
60–69 years	118	101 (85.6%)	42 (35.6%)	12 (10.2%)	0.41	0.58
70–79 years	120	108 (90.0%)	68 (56.7%)	26 (21.7%)	0.04	0.65
≥80 years	104	88 (84.6%)	46 (44.2%)	20 (19.2%)	0.13	0.39
≥50 years	438	378 (86.3%)	185 (42.2%)	66 (15.1%)	0.33	0.81
Median pain severity	6.5 (1–10)	6 (1–10)	5.3 (1–10)
Pain intensity (score)
Mild (1–2)		50 (11.0%)	17 (8.5%)	7 (10.0%)	0.84	0.71
Moderate (3–6)		178 (39.3%)	103 (51.8%)	42 (60.0%)	0.02	0.42
Severe (≥7)		225 (49.7%)	79 (39.7%)	21 (30.0%)	0.02	0.25
Clinically significant pain (score 3–10)
With pain		403 (68.4%)	183 (31.1%)	63 (10.7%)
< 50 years	151	65 (43.0%)	13 (8.6%)	3 (2.0%)	0.03	0.57
50–59 years	96	73 (76.0%)	27 (28.1%)	7 (7.3%)	0.21	0.52
60–69 years	118	86 (72.9%)	38 (32.2%)	10 (8.5%)	0.37	0.46
70–79 years	120	99 (82.5%)	64 (53.3%)	24 (20.0%)	0.05	0.71
≥80 years	104	80 (76.9%)	41 (39.4%)	19 (18.3%)	0.10	0.29
≥50 years	438	338 (77.2%)	170 (38.8%)	60 (13.7%)	0.36	0.86
Median pain severity	7 (3–10)	6 (3–10)	6 (3–10)
Pain intensity (score)
Moderate (3–6)		178 (44.2%)	104 (56.8%)	42 (66.7%)	0.02	0.38
Severe (≥7)		225 (55.8%)	79 (43.2%)	21 (33.3%)	0.02	0.29

Table 5. Factors associated with PHN in patients with herpes zoster.

Characteristics	PHN	HZ without PHN (N = 519)	OR (IC 95%)	p-value	aOR (IC 95%)	p-value
Age
< 50 years	4 (2.6%)	147 (97.4%)	Ref.		Ref.
50–59 years	8 (12.1%)	88 (23.6%)	3.34 (0.98–11.42)	0.05	1.23 (0.32–4.71)	0.76
60–69 years	12 (18.2%)	105 (28.5%)	4.16 (1.31–13.26)	0.02	2.05 (0.60–6.97)	0.25
70–79 years	26 (39.4%)	94 (25.3%)	10.16 (3.44–30.05)	< 0.01	4.26 (1.36–13.37)	0.01
≥80 years	20 (30.3%)	84 (22.6%)	8.75 (2.89–26.46)	< 0.01	3.89 (1.18–12.84)	0.03
Sex
Male	30 (42.9%)	217 (41.8%)	Ref.
Female	40 (57.1%)	302 (58.2%)	0.96 (0.58–1.59)	0.87
Presence of pain at rash onset
Yes	70 (100%)	386 (74.4%)	–	< 0.01
No	0 (0%)	133 (25.6%)	Ref.
Pain score at rash onset
No or 1–2	3 (4.3%)	180 (34.9%)	Ref.		Ref.
3–6	9 (12.9%)	169 (32.8%)	3.20 (0.85–12.00)	0.08	3.88 (0.81–18.49)	0.09
≥7	58 (82.9%)	167 (32.4%)	20.84 (6.41–67.78)	< 0.01	19.74 (4.63–84.10)	< 0.01
Eruption site
Thoracic	20 (28.6%)	186 (35.8%)	0.72 (0.41–1.24)	0.23
Other	50 (71.4%)	333 (64.2%)	Ref.
Pre-existing medical conditions
Yes	27 (38.6%)	166 (32.0%)	1.34 (0.80–2.24)	0.27
No	43 (61.4%)	353 (68.0%)	Ref.
Immune suppressive disease or therapy
Yes	4 (5.7%)	35 (6.7%)	0.84 (0.29–2.43)	0.74
No	66 (94.3%)	484 (93.3%)	Ref.
Comorbidities
Autoimmune disease	2 (2.1%)	11 (2.1%)	1.36 (0.29–6.26)	0.69
Chronic respiratory disease	1 (1.4%)	8 (1.5%)	0.93 (0.11–7.51)	0.94
Cardiovascular disease	8 (11.4%)	37 (7.1%)	1.68 (0.75–3.77)	0.21
Chronic renal disease	4 (5.7%)	12 (2.3%)	2.56 (0.80–8.17)	0.11
Diabetes mellitus	2 (2.9%)	37 (7.1%)	0.38 (0.09–1.63)	0.19	0.29 (0.07–1.31)	0.11
Depression/anxiety/stress	5 (7.1%)	39 (7.5%)	0.95 (0.36–2.49)	0.91
Hypothyroidism	7 (10.0%)	47 (9.1%)	1.12 (0.48–2.58)	0.80
Antiviral treatment
Yes	54 (90.0%)	335 (70.7%)	3.73 (1.57–8.88)	0.01
No	6 (10.0%)	139 (29.3%)	Ref.

Full text

Introduction

1

Varicella-zoster virus (VZV) is an alphaherpesvirus that causes two diseases in humans: chickenpox, the primary infection, and herpes zoster (shingles), caused by the endogenous reactivation of viruses that persist latently in the cranial and spinal sensory root ganglia after primary infection (1–3).

In Barcelona (Catalonia, Spain), as in developed countries, VZV infection especially affects very young children (4, 5). Before the introduction of the varicella vaccination, 82, 92, and 94% of children aged 5–9, 10–14, and 15–34 years became infected, and nearly all persons aged ≥50 years were infected (4, 5). This means that nearly 100% of the adult and elderly population of Barcelona harbor VZV in their sensorial ganglia, and this situation persists as long as cellular immunity against the virus is maintained. If immunity wanes, due to a medical or environmental condition that affects cellular immunity or due to age-related immunosenescence, the virus may affect the skin and cause herpes zoster (HZ) (2, 6). Latent infection occurs in most primary VZV infection cases, but only around 30% of infected persons will develop HZ at some point in their life, while 50% of persons who reach the age of 85 years without HZ will develop HZ (6, 7).

In Catalonia, the varicella vaccine was included in the recommended immunization schedule in 2005 with two doses at age 12 years. In 2016 it was changed to doses at 15 months and 3 years. Herpes zoster vaccine was included in 2022 in the recommended immunization schedule with 2 doses for people aged 65 or 80 years. Varicella vaccination is highly effective, with the transition to 2-dose schedules significantly reducing varicella incidence without increasing herpes zoster rates as initially hypothesized by some authors (8, 9). Both varicella and herpes zoster vaccines have demonstrated favorable safety profiles, including the combined MMRV vaccine (10) and the more recent recombinant adjuvanted herpes zoster vaccine, even in high-risk immunocompromised populations (11).

Clinically, HZ is characterized by a vesicular eruption of unilateral metameric distribution, in many—but not all—cases accompanied by pain, and limited in most cases to the dermatome innervated by a single sensory cranial or spinal ganglion, although the disease can also affect several dermatomes at the same time (2, 3). In many cases, rash onset is preceded by pain, paraesthesia, itching, and other forms of neurological discomfort in the involved dermatome, lasting several days and sometimes a week or more (2, 3, 12). This prodromal pain is only diagnosed when the rash develops, and consequently, other pain-causing diseases are frequently suspected, leading to numerous primary care and emergency department visits (2, 12).

HZ is a common disease, with similar annual incidence in most countries (four per 1,000 inhabitants in Europe). HZ incidence increases with age and mainly affects older people and women (6, 7, 12–15), and many patients have risk factors and underlying chronic diseases (3, 13, 15). Specific antiviral treatments are available, but even if administered immediately after rash onset, they rarely prevent complications, the most serious of which are postherpetic neuralgia (PHN) and ocular conditions (3, 14). In recent years, HZ incidence has been increasing (15–19), attributed to population aging and the emergence of new treatments for chronic diseases that lead to immunosuppression (16–19). All in all, HZ constitutes an important public health problem (15, 16), as the pain experienced represents a significant burden for the healthcare system and affects the patient's quality of life (12, 13).

In addition to its clinical impact, herpes zoster and postherpetic neuralgia are associated with a substantial economic burden. An economic burden study of herpes zoster in Spain reported that the disease generates substantial direct and indirect costs, significantly higher in patients with NPH (20), supporting the relevance of herpes zoster and PHN as a major public health concern.

Since the availability of attenuated vaccines (21) and inactivated vaccines (22) (2006 and 2016, respectively), there has been extensive research into HZ epidemiology and vaccination cost-effectiveness. Although HZ incidence has been well-documented (23–25), relatively little is known regarding the clinical-epidemiological characteristics of HZ prodromal pain, acute pain (0 days after rash onset), and subacute pain (30–90 days after rash onset).

The aim of the study was to analyse the clinical-epidemiological characteristics of HZ and PHN in cases diagnosed between 2007 and 2020.

Materials and methods

2

Included in the case series were all HZ and PHN diagnoses carried out during the years 2007 and 2020 within the first 14 days after rash onset in dermatology department and outpatient clinics of Hospital del Sagrado Corazón. The Hospital del Sagrado Corazón is a hospital located in Barcelona, Spain, with approximately 350 inpatient beds, which annually attend to approximately 24,000 hospital discharges, 52,000 emergencies and more than 350,000 outpatient visits.

HZ was defined as a vesicular rash with a unilateral metameric distribution, usually presenting with pain at the eruption site. The diagnosis was clinical in almost all cases, with the polymerase chain reaction (PCR) test reserved for doubtful cases (26). Prodromal pain was defined as any neurological pain or discomfort at the HZ eruption site before rash onset. PHN was defined as a unilateral metameric pain that persists for 90 days after rash onset.

Pain and discomfort related to the prodromal, acute, and subacute phases of HZ and PHN were measured according to Zoster Brief Pain Inventory criteria (21, 27), which, using an 11 point scale (0 = no pain to 10 = pain as bad as can be imagined), measures the severity of current, least, worst, and mean pain and discomfort in the previous 24 h. This instrument, used in the Shingles Prevention Study,16 has been widely demonstrated to have good reliability and validity.

An initial diagnostic visit was conducted, followed by biweekly follow-up visits until healing was achieved. If clinically significant pain persisted, PHN follow-up was extended to 18 months.

In our research, pain was “the worst pain” experienced by the patient in the 24 h prior to each dermatology visit and to enable comparison of our pain indicators with those of other studies, we used two criteria: “any pain” and “clinically significant pain” (scored 1–10 and 3–10, respectively). HZ and PHN cases were also recorded as classically diagnosed, i.e., without taking pain into account in the case definition.

On day 0 of rash diagnosis, HZ cases were classified into three categories: no pain (score 0), any pain (score 1–10), and clinically significant pain (score 3–10). PHN cases were classified in two groups: any pain (score 1–10) and clinically significant pain (score 3–10).

Collected variables included age, sex, eruption site, presence of pain, pain intensity at diagnosis and during follow-up (day 0, day 30, and day 90), duration of pain, immune suppressive disease or therapy, comorbidities and antiviral treatment. Clinical and epidemiological data were collected prospectively from patients' hospital visits.

Bivariate comparisons were performed using Pearson's chi-square test for categorical variables, and trend was assessed using the chi-square trend test. Crude odds ratio (OR), adjusted OR (aOR), and 95% CI values were estimated using logistic regression. Adjusted OR values were calculated using the logistic regression model with backward variable selection, with a cut-off point of p < 0.2. Differences were considered statistically significant for p < 0.05.

Ethical considerations

2.1

The data were collected retrospectively in December 2024. All data collected from patients were treated as confidential, in strict observance of the legislation on observational studies. The study was approved by the Hospital del Sagrado Corazón ethics committee (2024/92-DER-HUSC).

Results

3

589 cases of HZ were included, 342 (58.1%) were women and median was 63 (6–99) years. Table 1 describes HZ cases by age and gender according to the two pain categories (any pain and clinically significant pain). Women compared to men predominated overall, although men predominated in the < 20 age groups. The female/male ratio overall was 1.38, and was slightly greater in both the any pain (1.53) and clinically significant pain (1.57) categories.

HZ diagnoses clearly increased with age (p < 0.01), irrespective of the pain category. The lowest number of cases occurred in children aged 0–9 years and adults aged 20–29 years, and the highest number of cases occurred in the 70–79 age group (followed by the 60–69 age group), after which cases dropped in the ≥80 age group.

Table 2 shows eruption site details for the < 50 years and ≥50 age groups. Overall, the thoracic dermatome (35.0%) was most affected, followed at a distance by the lumbar (19.8%), cranial (18%), sacral (14.6%), and cervical (11.9%) dermatomes. For both any pain and clinically significant pain, proportions were higher in the ≥50 age group, with the exception of the thoracic and cranial dermatomes, for which proportions were higher in the < 50 age group. Disseminated cases accounted for 0.7% of patients, and there were no cases of HZ sine herpete.

Table 3, summarizes pain at different HZ stages (day 0, at 30 days, and at 90 days) according to age group and pain category. On day 0, 133 patients (22.6%) had no pain, and the proportion of patients aged < 50 years with no pain (48.3%) was much higher than for patients aged ≥50 years (13.7%). For any pain, the percentage of cases on day 0 was 77.4%, decreasing to 34.5% at 30 days, and 11.9% at 90 days; percentages for clinically significant pain were slightly lower at 68.4% on day 0, 31.6% at 30 days, and 11.4% at 90 days. For both the pain categories and for all measurements, pain percentages for the < 50 age group were much lower than for the ≥50 age group (p < 0.01).

Table 4 summarize patterns according to age, revealing age distribution patterns that were similar for both pain categories, although proportions were slightly lower for the clinically significant pain category compared to the any pain category.

Pain at all stages increased progressively through the different age groups, peaking in the 70–79 age group and falling off thereafter. On day 0, for instance, any pain was 51.6% for the < 50 age group, peaked at 90% for the 70–79 age group, and fell to 84.6% for the ≥80 age group. Median pain severity was 6.5 (1–10), and 49.7, 39.3, and 11% of patients reported severe, moderate, and mild pain, respectively. The severe pain rate was significantly lower at 30 days (39.7%) than on day 0 (49.7%). Of the included cases, just 70 (11.9%) had any pain 90 days after rash onset, and their median pain severity was lower than on day 0 (5.3 vs. 6.5). The pain percentage at 90 days for patients aged 70–79 years (the age group with the highest incidence) was much lower than on day 0 (21.7% vs. 90%; p = 0.04). For clinically significant pain, the severe pain rate was significantly lower at 90 days (33.3%) than on day 0 (55.8%); p = 0.02.

Table 5 summarizes factors associated with PHN. Of the 589 cases, 70 (11.9%) progressed to PHN with a median age of 74 (44–91) years. Factors associated with PHN were age groups 70–79 years (aOR 4.26; 95% CI 1.36–13.37) and ≥80 years (aOR 3.89; 95% CI 1.18–12.87) and intensity of pain score at rash onset ≥7 (aOR 19.74; 95% CI 4.63–84.10).

Pain duration was 3–6 months for 56.1%, 7–12 months for 25.8%, 13–18 months for 6.1%, and >18 months for 12.1% of patients aged ≥50 with PHN.

Discussion

4

Our results confirm that women are at higher risk of developing HZ than men. In our study, HZ was more frequent in women in all age groups except for the youngest age groups (children and young people aged < 20 years), in which males predominated. For all the cases included in our series, the female/male ratio overall was 1.38, considerably higher than that of the entire population of Barcelona (1.05) in 2012 (halfway through the study period) (28); furthermore, this ratio increased even further for the any pain (1.53) and clinically significant pain (1.57) categories.

The vast majority of studies published in the last 20 years have reported statistically significant higher HZ rates in women compared to men. A meta-analysis by Kawai et al. (29), which included 27 studies with different designs carried out on five continents in the last 18 years, reported that women were consistently at greater risk of developing HZ than men (pooled effect estimate: relative risk (RR) 1.31; 95% confidence interval (CI) 1.27–1.34). The pooled effect estimate was somewhat lower in the meta-analysis by Marra et al. (30), which included 56 studies (RR 1.19; 95% CI 1.14–1.24). In another systematic review it was found that the female/male ratio of HZ cases was 1.1 (31). A study carried out in Spain found that HZ was more frequent in women than in men (32), and in a study carried out in China, women had a slightly higher incidence rate than men (7.9 vs. 7.6%) (33).

Some authors suggest—possibly implausibly—that the gender differences may be due to women's greater healthcare-seeking behavior. However, gender differences similar to those of the above-mentioned meta-analyses were reported for the placebo group of the Oxman et al. study (21), based on PCR diagnosis and exhaustive follow-up for 3 years. Our results pointing to a higher rate of HZ in males aged < 20 years compared to adults aged ≥20 years (predominantly women) would suggest an endogenous difference between males and females, probably of a hormonal or immunological nature (30, 34).

For many years, before the chickenpox vaccine was included in routine vaccination schedules, it was hypothesized that cellular immunity in the adult population would be periodically reinforced by viral exposure through contact with children (35). If this were the case, since it is women who usually care for sick children, female cellular immunity would be strengthened relative to that of males; consequently, incidence of HZ in women would be lower and would require less immunity boosting. Our results, however, would point to a rejection of this hypothesis, as does a Japanese study of pediatricians who theoretically would be more exposed to the virus (36), and as does a French study of cloistered nuns with no relationship with children over their entire lives (37).

Our study also confirms the increase in HZ incidence with age, corroborating most other similar studies. A systematic review found than age was identified as a major risk factor toward HZ incidence which increase significantly in people >50 years of age (31). Yang et al. (33) found that rates of HZ increased with age and were highest in patients aged ≥70 years and Masa-Calles et al. (32) also found that the incidence of HZ increased with age. The explanation for the age association, better grounded than that of the gender association, is cell immunosenescence linked to aging and to diseases that depress immune systems (38–41). As reported in most other similar studies, in our study, incidence peaked in the 70–79 age group and declined from age 80 onwards. There is no clear explanation for this decline in the elderly, as cellular immunity continues to decrease after the age of 80 years. Some authors hypothesize that illness in this age group is less likely to be recorded in official statistics, given the higher prevalence of disabling chronic diseases that hinder mobility and so lead to more home-based treatment by family doctors rather than in outpatient clinics or primary care centers (39, 42, 43).

In our study, and corroborating most other studies, the thoracic dermatome was most affected, followed at a distance by the lumbar dermatome, and then—contrary to most studies (41–45)—by the cranial dermatome, probably because patients with ocular involvement, alarmed by dramatic signs and symptoms, go directly to the ophthalmologist rather than to the dermatologist. Some authors have posited a possible role for specific dermatomes, most especially the trigeminal dermatome, in PHN development, although a meta-analysis by Forbes et al. (45) was unable to conclusively demonstrate this role. In our study, distribution according to the affected dermatome of HZ cases with progression to PHN was similar to that for non-progression to PHN, which would suggest that rash site is not a risk factor for this complication.

To our knowledge, ours is the first study of the epidemiology of HZ and PHN carried out in Spain in the form of a single-center and single-dermatologist study. HZ cases have been classified in three pain categories: no pain (score 0), any pain (score 1–10), and clinically significant pain (score 3–10). Pain incidence on diagnosis was relatively high, but decreased significantly after 30 days of evolution, from 77.4 to 34.5% of patients. Noteworthy was the fact that the proportion of cases with significant clinically pain (3–10) was 68.4% at 0 days and 31.1% at 30 days compared to 77.4 and 34.5%, respectively, for any pain (1–10).

The incidence of pain on diagnosis clearly increased with age in our study, corroborating the majority of published studies (13, 15, 29, 30, 46). While the percentage of patients with pain on day 0 was relatively high (77.4%), it decreased significantly by 30 days (34.5%). However, mean pain intensity did not decrease in the same proportion over the same period, contrasting with other studies reporting that mean pain intensity decreased significantly between 0 and 30 days after rash onset (47–51).

PHN incidence, like that of HZ, clearly increased with age. For patients with HZ, the mean age of progression to PHN was significantly higher (72 years) than for patients with non-progression (58 years), reflecting a significant difference of 14 percentage points; this would suggest that age at diagnosis is an important risk factor for PHN in patients with HZ. Yang et al. (33) also found that rates of PHN increased with age. In a study carried out in Saudi Arabia it was found that a significant predictor of NPH was age ≥50 years (52).

Finally, noteworthy is the fact that PHN duration was 3–12 months in 81.9%, 13–18 months in 6.1%, and >18 months in 12.1% of patients aged ≥50 years (8 of the PHN cases continued to experience pain 18 months post-onset). Other authors have found similar values, most patients had PHN-related pain for < 1 year (80.5%), with only a small proportion having PHN-related pain for ≥5 years (4.3%) (33).

The main strength of our study is that all patients were diagnosed and registered by the same experienced dermatologist (Dr Salleras, director of our hospital dermatology department), thereby avoiding interpersonal variability, which avoided the biases that often occur in diagnoses and data transcription from primary healthcare or hospital records to computerized databases. In an epidemiological study in Olmsted County (USA), Yawn et al. (53) compared medical record review and administrative database estimates of HZ rates and complications, finding a difference in HZ occurrence of 14.5%; while differences of 15%−18% may be acceptable for incidence or trend studies, they are clearly excessive when greater precision is required, e.g., for economic studies. Other recently published studies have also found significant differences between administrative databases and medical records for case and vaccination data (54, 55).

A key strength differentiating our study from most similar studies is that patients of all ages (children, adolescents, young adults, and older adults) were included. Many studies published since vaccines became available include persons who are the usual target of vaccination programmes, i.e., aged ≥50 years in whom the HZ incidence is higher. Our inclusion of a broader range of ages shows that HZ and PHN also affect people aged < 50 years, and also confirms less severe clinical characteristics compared to persons aged ≥50 years.

Another strength is that pain intensity data was recorded by the same specialist, reflecting a single criterion in the interpretation of pain. Moreover, incidence was calculated using same definitions from recently published studies, i.e., three categories for HZ and two categories for PHN, thereby enabling comparison with other studies that use the same definitions.

Since our study was based on data for patients with HZ and PHN visiting mostly a dermatology outpatients clinic, the included cases may be more severe than those treated in primary care. Likewise, the fact that the subjects included in the study were healthcare-seeking patients likely explains the greater severity in our series compared to experimental studies implemented to evaluate the two marketed vaccines. In those latter studies, cases were detected among persons randomly included in the vaccinated and control groups, and consequently, those with mild HZ who did not seek medical attention would have been excluded.

Regarding study limitations, other than for PHN in HZ cases, HZ incidence and complication rates could not be calculated, since 70% of persons treated by the dermatology outpatient clinic were referred from attached primary care centers, while the remaining 30% were referrals, according to the criteria of insurance companies, of residents of other areas of Barcelona and even of Catalonia. A further limitation (inherent to all epidemiology studies) is our non-inclusion of catchment-area patients who did not seek medical care for a mild form of HZ or who sought private care.

Finally, rash lesions have only been counted since 2021, so the data available on this variable are currently insufficient to draw statistically significant conclusions. Likewise, prodromal pain data have only been collected since 2014, resulting in a relatively small sample size and reducing the probability of detecting statistically significant differences in any possible associations.

During the study period, the herpes zoster vaccine was not available in the immunization schedule of Catalonia. Real-world evidence demonstrates that recombinant zoster vaccine safety and provides protection in high-risk populations (56), and a reduction in herpes zoster incidence among immunocompromised patients (57, 58). Future studies should incorporate vaccination status to better evaluate the impact of herpes zoster vaccination campaigns, particularly in frail and immunocompromised populations who benefit most from preventive strategies.

Despite the availability of antiviral therapy, the management and prevention of postherpetic neuralgia remain limited, with current treatments showing modest effectiveness. Recently, a case report described rapid symptom resolution and a shortened duration of PHN in a patient with severe herpes zoster ophthalmicus treated with a combination of an immunostimulatory vaccine virus and acyclovir (59). Although based on a single case, these findings highlight the potential of novel combination therapies and the need for further research into more effective treatment strategies for PHN.

Our study would confirm, as other authors have found (60), that pain presence and intensity at 0 and 30 days after HZ diagnosis and the patient's age are the main risk factors for PHN development. In recent years it has been observed that 14-day famciclovir administration and combined high-voltage radiofrequency and oxygen-ozone treatment may have some therapeutic and perhaps also preventive benefits in managing PHN. Our findings, if confirmed by other studies, could be used in clinical diagnosis to select patients who are more likely to develop PHN and who would benefit most from treatment.